Sangamo Therapeutics (SGMO)

• Market cap: $223M
• 1 day: -4.46%
• 5 days: -8.55%
• 1 month: -5.31%
• 3 months: -45.41%
• 6 months: 22.29%
• Year to date: -5.31%
• 1 year: -13.71%
• 5 years: -85.62%
• 10 years: -93.73%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Employees: 405

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

29% more capital invested

Capital invested by funds: $48.7M [Q3] → $62.8M (+$14.1M) [Q4]

23% more funds holding

Funds holding: 103 [Q3] → 127 (+24) [Q4]

2.48% more ownership

Funds ownership: 26.99% [Q3] → 29.47% (+2.48%) [Q4]

3% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 30

44% less call options, than puts

Call options by funds: $1.87M | Put options by funds: $3.36M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 87% upside
• Avg. target: $5 367% upside
• High target: $10 835% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 43% 1-year accuracy 76 / 175 met price target	835% upside $10	Buy Reiterated	27 Jan 2025
Truist Securities Nicole Germino 64% 1-year accuracy 7 / 11 met price target	367% upside $5	Buy Maintained	23 Jan 2025
Jefferies Maury Raycroft 9% 1-year accuracy 1 / 11 met price target	180% upside $3	Buy Maintained	31 Dec 2024
Wells Fargo Jim Birchenough 0 / 0 met price target	87% upside $2	Equal-Weight Maintained	31 Dec 2024